

Very strong revenue growth in the first half of 2016: +36%

- Another surge in sales of LISA TRACKER® kits: +150%
- 74% of revenues generated by in-house products (internal)

Croissy-Beaubourg and Montpellier, July 5, 2016 – Theradiag (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in *in vitro* diagnostics and theranostics, has today reported its consolidated revenues for the first half of 2016.

“Theradiag’s excellent sales performance in the first six months of 2016 is a ringing validation of the strategic goals we have set. The sales growth achieved by our Theranostics unit (Lisa Tracker®) reflects clinicians’ interest in biotherapies monitoring products”, commented Prof. Gérard Tobelem, Theradiag’s Chairman.

<i>In thousands of euros</i>	Six months to June 30, 2016	Six months to June 30, 2015	Change
Revenues	4,631	3,416	+36%
<i>o/w Lisa Tracker® revenues</i>	1,672	660	x2,5
<i>o/w IVD revenues</i>	2,959	2,756	+7%

In the first half of 2016, Theradiag recorded a 36% increase in its consolidated revenues to €4.6 million. This increase was underpinned by the Theranostics business unit and the strong revenue growth in Lisa Tracker® kits (2.5x the total posted in the first six months of 2015).

Michel Finance, Theradiag’s Chief Executive Officer, added: *“The driving force behind this growth is built on the expansion in our sales territory and the benefits of our partnerships with pharma companies UCB and Hospira/Pfizer. Based on this latest set of figures, we confidently expect to hit our end-of-year revenue targets. The launch of our gastroenterology tests in the United States will provide a further top-line boost from 2017 onwards.”*

In addition, the IVD business unit recorded revenue growth of 7% on the back of new high value-added distribution ranges.

Second-quarter 2016 revenues totaled €2.4 million, up 12% on the first quarter of 2016.

Two events unlocking future growth opportunities for Theradiag took place in the second quarter of 2016:

- The new BioCLIA® 1200 instrument, a co-development with our Chinese partner HOB Biotech that will reinforce our activities in auto-immune diseases and allergy, was presented at the Leipzig conference.
- Our partner Miraca Life Sciences launched the first four kits in the Lisa Tracker® range, opening up access to the American market.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com



Theradiag

Investor Relations

Fabienne François

CFO

+33 1 64 62 10 12

contact@theradiag.com

NewCap

Financial communications/
investor relations

Valentine Brouhot/

Pierre Laurent

+33 1 44 71 94 94

theradiag@newcap.eu

Alize RP

Press

Caroline Carmagnol/

Florence Portejoie

+33 1 44 54 36 64

theradiag@alizerp.com